Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICH-2 is a traditional Chinese herbal medicine formula developed by the Guangzhou University of Traditional Chinese Medicine for the treatment of acute intracerebral hemorrhage (AICH). It consists of six herbs and is specifically formulated without "blood-activating and stasis-dispersing" (RBS) herbs such as Hirudo (leech) and Tabanus (gadfly), which are present in related formulas like ICH-1. ICH-2 serves as a non-blood-activating control in clinical trials, such as the CRRICH (Clinical Re-evaluation of Removing blood stasis therapy in treating acute intracerebral Hemorrhage) series, to evaluate the safety and efficacy of different herbal approaches in the early stages of cerebral hemorrhage. The formula aims to provide therapeutic benefits while avoiding the potential risk of enlarging brain hematomas associated with potent blood-stasis-removing agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ICH-2.